this study was designed to evaluate whether plasma asymmetric dimethylarginine (aDMa) has any role in predicting hemodynamic responses in clinically healthy young subjects. aDMa, as an endogenous nitric oxide (NO) synthase inhibitor, has been demonstrated to associate with hypertension and vascular reactivity in experimental but not undoubtedly in physiological settings.
Nitric oxide (NO) plays an important role in the regulation of important cardiovascular functions. 1 Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of NO synthesis, modulates NO production and has, therefore, been implicated e.g., in endothelial dysfunction and vascular disease. 2, 3 Parameters reflecting arterial stiffness have been observed to associate with an increased cardiovascular risk and hypertension. [4] [5] [6] It has been suggested that high plasma ADMA will lead to diminished NO bioavailability and, thereby, increased vascular resistance and elevated blood pressure (BP). 7 In fact, an experimental study demonstrated that intravenously dosed ADMA can significantly increase systemic vascular resistance (SVR) and arterial BP. 8 However, in a more physiological setting with a small number of study participants, no association was observed between plasma ADMA and vascular physiology. 9 An association between circulating ADMA levels and BP has been reported in some studies 3, 7 but not in all. [10] [11] [12] Moreover, we have recently shown that plasma ADMA has an inverse association with systolic BP in the Young Finns Study population. 13 Thus, the relationship between ADMA and cardiovascular physiology is not fully established.
The current study was performed to examine further how plasma ADMA is associated with hemodynamic regulation in young clinically healthy subjects.
METHODS

Study population. Originally, the Cardiovascular Risk in Young
Finns Study is an on-going five-center follow-up study of atherosclerosis precursors in Finnish children and adolescents. In 1980, 4,320 children and adolescents aged 3-18 years (born articles ADMA and Vascular Tone in years 1962, 1965, 1968, 1971, or 1977) were randomly chosen from the Finnish Social Insurance Institution's population register of study areas. Of those invited, 3,596 participated in the cross-sectional study in 1980 (ref. 14) . In 2001, risk factors and arginine derivatives of 2,265 subjects were examined at age 24-39 years. 15 In 2003-2004, we examined the hemodynamic parameters in 243 subjects, who by then had reached the age of 25-42 years ( Table 1) . The final study population consisted of 199 participants when subjects on any medication were excluded. We classified the participants on the basis of repeated casual BP measurements according to the Joint National Committee classification. 16 One hundred of the participants were normotensive (systolic BP (SBP) <120 mm Hg and diastolic BP (DBP) < 80 mm Hg), 79 belonged to the prehypertensive group (PREHT) (SBP 120-139 mm Hg or DBP 80-89 mm Hg, or both), and 20 belonged to the stage 1 or stage 2 hypertensive group (HT) (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg, or both). The study was approved by local ethics committees and all subjects gave their written informed consent.
BP monitoring. BP was measured at the baseline using a random zero sphygmomanometer. Average of three measurements was used in the analysis. After 2 years follow-up, BP was measured with the participants in the supine position after 10 min of rest, using a calibrated aneroid barometer (Speidel and Keller, Jungingen, Germany). SBP was read at the first Korotkoff sound and DBP at the disappearance of the Korotkoff sounds (phase V). The deflation rate was 2 mm Hg/s.
Noninvasive hemodynamic study. BP was monitored by a finger blood-pressure measurement method (Finapres 2300, series FAX; Ohmeda, Louisville, CO), which provides continuous noninvasive monitoring of beat-to-beat BP, and is, therefore, an useful noninvasive alternative to intra-arterial BP measurements. 17 Cardiac output [(CO) = heart rate × stroke volume] was measured using whole-body impedance cardiography (CircMon, Model B202; JR Medical, Tallinn, Estonia). This method is described in detail elsewhere. 18 Briefly, the whole-body impedance cardiography channel of CircMon B202 is based on the Tishchenko 19 stroke volume equation with a correction factor for tetrapolar registration, and includes also a correction of stroke volume by hematocrit and body mass index. Disposable electrocardiogram electrodes (Blue sensor type R-00-S; Medicotest A/S, Ølstykke, Denmark) were used. A pair of electrically connected current electrodes was placed on extremities, just proximal to wrists and ankles. Voltage electrodes were placed proximal to the current electrodes with a 5-cm distance between the centers of the electrodes. Whole-body impedance cardiography reliably measures CO and has an excellent agreement with invasive thermodilution and direct oxygen Fick methods for measuring CO in subjects without cardiac shunts and valvular lesions. 18 Thus, this method is a feasible and handy technique for a noninvasive and continuous analysis of CO and its changes in different conditions. CO was related to the surface area of the subjects, and it was transformed to the respective index: (cardiac index (CI) = CO × m 2 ). SVR was calculated from CO and mean arterial pressure as SVR = mean arterial pressure/CO × 80. Arterial pulse wave velocity (PWV) was obtained from the time delay between simultaneously recorded flow pulses and the distance between recording sites, i.e., between the root of aorta and popliteal artery, a method which we have found to show a good agreement with measurements of pulse transition in arterial tree by ultrasound-determined Doppler-flow method. 20 Arterial pulse waves were recorded with voltage-sensing channels of the CircMon B202 and analyzed automatically with the same device. Pulse transition in aortic root was estimated from the whole-body impedance cardiogram at the point where a sharp systolic upstroke commenced. The pulse wave arrival to the popliteal artery was similarly estimated from the sharp systolic upstroke of the second channel with the active electrode placed at the knee joint level. The distance between the aortic root and the knee joint was estimated from the subject's height (H) by using a ratio H/1.61.
SVR was related to the surface area of the subjects, and it was transformed to the respective index: (SVR index (SVRI) = SVR × m 2 ).
The subject was kept in supine position during the first 10 min of the hemodynamic monitoring, followed by a transition to head-up tilt position (60°) on the tilt table for 5 min. At 15 min from the start, the subject was again tilted down to supine position for another 5 min. Hence, the total duration of Values are mean ± s.d. BMI, body mass index; DBP, diastolic blood pressure; F, female; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HT, hypertensive; LDL, low-density lipoprotein; M, male; N, no; NT, normotensive; PREHT, prehypertensive; SBP, systolic blood pressure; TC, total cholesterol; TGs, triglycerides; Y, yes. *P < 0.05 vs. NT subjects, **P < 0.01 vs. NT subjects, ***P < 0.001 vs. NT subjects, § † P < 0.05 vs. PREHT subjects, † † P < 0.01 vs. PREHT subjects, † † † P < 0.001 vs. PREHT subjects.
articles ADMA and Vascular Tone data acquisition was 20 min. During the study the subject was not allowed to speak.
Determinations of plasma lipids, glomerular filtration rate, and arginine derivatives. Venous blood samples were drawn after an overnight fast at the baseline. All lipid determinations were done on serum using standard methods. Estimated glomerular filtration rate (GFR) was calculated with the Cockroft-Gault formula: for men, GFR = [(140 − age) × weight (in kg)]/(72 × creatinine (in mg/dl); for women, GFR = 0.85 × [(140 − age) × weight (in kg)]/(72 × creatinine (in mg/dl)). 21 Arginine, ADMA, and symmetric dimethylarginine (SDMA) concentrations were determined by isocratic high-pressure liquid chromatography using precolumn derivatization with o-phtaldialdehyde modified from the method described by Teerlink et al. 22 Plasma proteins were precipitated from 200 μl plasma with trichloroacetic acid, 10 μmol/l monomethylarginine added as internal standard and after centrifugation applied on a solid-phase extraction cartridge (MCX, OASIS; Waters Corp, Milford, MA 
RESULTS
Arginine derivatives, lipids, and renal function
The average plasma l-arginine, ADMA, and SDMA concentrations in all subjects were 122 ± 33, 0.65 ± 0.15, and 0.44 ± 0.09 µmol/l, respectively. The results were similar both in women and men. Plasma lipids did not associate with plasma arginine derivatives. No statistically significant association either was observed between plasma arginine derivatives and GFR, although an association between plasma SDMA and GFR was borderline significant (r = −0.14, P = 0.06).
Arginine derivatives and BP
Baseline BP values correlated strongly with the BP values after the follow-up (SBP; r = 0.73, P < 0.0001 and DBP; r = 0.66, P < 0.0001). Plasma ADMA concentrations were inversely correlated with the DBP values after the follow-up (r = −0.15, P < 0.05) but not with DBP at baseline (r = −0.06, P = 0.43). No significant association was observed between plasma ADMA and SBP at baseline (r = −0.12, P = 0.09) or after the follow-up (r = −0.11, P = 0.11). Plasma arginine, arginine/ADMA ratio, and SDMA did not associate with BP values at baseline or after the follow-up either (data not shown). Plasma l-arginine, ADMA, and SDMA concentrations as well as arginine/ADMA ratios were comparable in all BP groups (NT, PREHT, HT) ( Table 2) . We also compared BP values in all plasma ADMA quartiles and found that systolic as well as diastolic BP values were comparable in all quartiles. The results were similar also in smokers and nonsmokers.
Arginine derivatives and other hemodynamic parameters
There was a significant difference between BP groups (NT, PREHT, HT) in resting SVRI (P < 0.001; higher the BP group, higher the SVRI) and PWV (P < 0.001; higher the BP group, faster the PWV). This was seen both in women and men as well as in smokers and nonsmokers. Plasma ADMA correlated inversely with SVRI (r = −0.23, P < 0.01; Figure 1 ) and PWV (r = −0.17, P < 0.05) and directly with CI (r = 0.21, P < 0.01; Figure 1 ). Plasma SDMA did not associate with SVRI (r = −0.11, P = 0.14), PWV (r = −0.09, P = 0.23), or CI (r = 0.07, P = 0.32). No correlation was observed between plasma arginine or arginine/ADMA ratio and hemodynamic parameters either (data not shown).
We next tested how plasma ADMA associates with hemodynamic responses in a head-up tilt test. This was performed by measuring a difference in SVRI, PWV, and CI in rest and after 1 min of hemodynamic test. ADMA correlated indirectly with SVRI response (r = −0.19, P < 0.01) and directly with CI response (r = 0.25, P < 0.001; Figure 2 ). This was particularly evident in men (SVRI; r = −0.31, P < 0.01 and CI; r = 0.36, P < 0.001, respectively). In women, the association was not significant. Tendency of the responses in smokers and nonsmokers was similar as in all subjects but was not statistically significant. The associations between plasma ADMA and hemodynamic parameters and also between plasma ADMA and hemodynamic responses were similar also after exclusion of hypertensive subjects (data not shown). 
Linear multivariable analysis
In a multivariable linear regression analysis (R 2 = 0.20, P < 0.00001). the significant predictors of resting SVRI were diastolic BP (R = 0.37, P < 0.00001) and ADMA (R = −0.20, P < 0.01). The other explanatory variables in the model were arginine, total cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass index, age, gender, and smoking status.
DISCUSSION
The main finding of this study is summarized as follows: BP and plasma ADMA associated significantly with hemodynamics in rest and also with hemodynamic responses in the head-up tilt testing. In some previous studies, a significant association between plasma ADMA and BP has been observed. 3, 7, 23 High plasma ADMA, may lead to diminished NO bioavailability and, there by, to increased vascular resistance and elevated BP. 3 This assumption was supported by experimental studies in which intravenously administered ADMA significantly increased systemic vascular resistance and arterial BP 8 and lowered CO. 8, 24 However, Delles et al. 10 did not find any correlation between plasma ADMA concentration and BP in young men with mild essential hypertension. Furthermore, we have not found in our earlier studies any direct association between BP and plasma ADMA in young or old subjects, 9,11,12,25,26 although we found that borderline hypertensive young men had significantly higher plasma ADMA levels compared to controls 25 and that ADMA associated significantly with systolic and diastolic BP in middle-aged mildly hypercholesterolemic subjects avoiding alcohol. 26 In a recent study, we evaluated the association between plasma ADMA and hemodynamic regulation in apparently healthy middle-aged men and found no association between plasma ADMA and BP or other hemodynamic parameters. 9 However, we recently showed in the total Young Finns population that plasma ADMA has a significant inverse association with systolic BP. 13 Thus, the relationship between ADMA and cardiovascular physiology is not established fully. In this study, we aimed to further clarify the role of plasma ADMA in the regulation of BP and vascular functions in the subpopulation of the Cardiovascular Risk in Young Finns Study.
Because plasma ADMA is an endogenous competitive inhibitor of NO synthase 2 and can modulate endogenous vasodilator NO 27 production, one can suppose that plasma ADMA may be associated with BP or other hemodynamic regulation not only in experimental settings but also in normal human physiology. In this study, we evaluated 199 clinically healthy young subjects without any medication and observed the wellknown 4 association between BP and vascular resistance. We evaluated plasma ADMA levels in different BP groups and found that normotensive, prehypertensive, and hypertensive subjects had similar plasma ADMA levels. Despite this finding, we observed in a univariate analysis a significant association between plasma ADMA and diastolic BP and an inverse tendency between plasma ADMA and other BP values which was in line with the finding of considerably larger (n = 2094) cohort of this study. 13 In addition, this study demonstrated, contrary to earlier findings of the experimental studies, 8, 24 a negative correlation between plasma ADMA and vascular resistance and a positive correlation between ADMA and CI. Similar associations were also seen between ADMA and SVRI and CI responses in a hemodynamic challenge test. In addition, plasma ADMA was a significant determinant for SVRI in a linear multivariate regression analysis. In a recent experimental study, intravenously administered subpressor doses articles ADMA and Vascular Tone of ADMA increased arterial stiffness and decreased cerebral blood flow in young healthy men. 28 Another study demonstrated an association between plasma ADMA and aortic stiffness in elderly patients undergoing coronary angiography for assessment of suspected coronary artery disease. 29 In that study, many of the patients were on a medication (including nitrates and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers) during the study, which may have altered wave reflections as well as ADMA levels. Contrary to those earlier findings, 28, 29 we demonstrated a negative association between plasma ADMA and arterial stiffness (PWV) in this study. Plasma SDMA did not associate with hemodynamics. Previously, it has been demonstrated that plasma SDMA tightly correlates with estimated GFR. 30 In this study, we observed only a borderline significant negative correlation between plasma SDMA and estimated GFR. An explanation for that may be that study subjects were young and apparently healthy and they had a normal renal filtration with a narrow range.
The findings of the experimental studies 8, 24 suggest strongly that plasma ADMA in high doses is a biologically active regulator of vascular tone and produces adverse cardiovascular effects in humans. However, in more physiological settings, plasma ADMA seems to have an opposite role in apparently healthy young humans. It is possible that this cannot be observed in elderly subjects or subjects with vascular disease who may have elevated plasma ADMA levels as a consequence of vascular disease. Based on findings of our previous study 13 and the recordings of this study, we suggest that in a physiological setting ADMA levels in subjects with elevated vascular tone may actually be lowered to compensate for inappropriately high resistance. The increase in CI is probably mostly a compensatory reaction after the attenuation of SVRI. Thus, one may suggest that ADMA can have a dual role in the regulation of vascular tone; high ADMA levels e.g., due to genetic reasons, may lead to increased vascular tone but in subjects with no particular reason for high ADMA its cellular levels could perhaps be adjusted to maintain appropriate vascular resistance.
Overall, we suggest that plasma ADMA seems to have a regulative role in human hemodynamic physiology by determining vascular resistance in unselected young healthy subjects.
acknowledgments: this study was financially supported by the academy of Finland (grant nos. 77841, 210283, and 34316), the social Insurance Institution of Finland, the turku University Foundation, the Juho Vainio
